Phylogica provides the following update in relation to its current capital raising.
The capital raising:
- is being conducted at a price of 3 cents per share;
- is an excluded offer available to professional investors only and will introduce new sophisticated and institutional investors to Phylogica’s register;
- is being supported by the Company’s existing major shareholders; and
- will provide funding for three primary activities:
Completing the screening of PYC’s enriched drug libraries for ‘second generation’ Cell Penetrating Peptides (CPPs);
Reaching a definitive read-out on the ability of PYC’s CPPs to deliver a range of different therapeutic cargoes in therapeutic settings (either ex vivo or in vivo); and
Advancing its flagship program through to an Investigational New Drug (IND) filing in order to enable ‘first in human’ studies utilising the company’s CPPs.
For further information please download PDF attached:
Download this document
